Meanwhile, in the world of microbiology:
1) "Cepheid was able to leverage its extensive development experience to expedite delivery from the initial prototype to an emergency use only product in just 90 days (ebola assay)" The company also announced selling it's 10 millionth Xpert TB cartridge.
2) Becton Dickinson STD assays for the BD Max instrument receives the European CE mark.
3) Biomerieux Tempo instrument in use by the USDA's FSIS 3 regional testing centers.
Petro a few years ago-- “Me not so smart... just bought a few shares and now holding until the company agrees to a fair price to sell. If they don't guess I'll have to refer to Stan Weinsteins book for when to sell a Stage 3 or Stage 4 stock. Seems Stan recommended NEVER selling a stage 2 stock! “
"Stan divides a stock price chart into four regions: 1: Accumulation, 2: Ramp UP, 3: Topping, 4: Going DOWN! May you NEVER hold a Stage 4 stock!"
Wonder if he took up Weinstein's advice regarding stage 4 stocks?
Over 2 years ago--"Petro wrote "Since it's now been reported that Marathon now holds zero shares of NNLX, they have sold +1.7 million shares since the start of the year, when the share price was 30 cents/share.
Now that Marathon has finished selling, this pressure should be gone."
But there seemed to be a big sell-off during the course of Marathon's liquidation. And then a continued drop from .30 now down to .05